-+ 0.00%
-+ 0.00%
-+ 0.00%

China drug regulator accepts NDA filing for Roche-partnered Tam-Peli in relapsed small-cell lung cancer

PUBT·09/13/2026 00:00:28
Listen to the news
China drug regulator accepts NDA filing for Roche-partnered Tam-Peli in relapsed small-cell lung cancer
  • China’s NMPA drug review arm accepted an NDA filing for MediLink’s Tam-Peli in relapsed small-cell lung cancer.
  • Roche holds rights to develop and commercialize Tam-Peli outside mainland China, Hong Kong, and Macau.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609122000OMX_____CNEWS_EN_GNW1001262359_en) on September 13, 2026, and is solely responsible for the information contained therein.